Back to top
more

ACADIA Pharmaceuticals (ACAD)

(Delayed Data from NSDQ)

$18.75 USD

18.75
1,344,337

-0.39 (-2.04%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ACAD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

ACADIA Pharmaceuticals Inc. [ACAD]

Reports for Purchase

Showing records 141 - 160 ( 246 total )

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 141

08/01/2019

Company Report

Pages: 5

Strength in Underlying Business Frames Important Pipeline Catalysts Ahead

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 142

07/23/2019

Daily Note

Pages: 5

Our Thoughts Following the Topline Miss of the Phase 3 ENHANCE study

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 143

05/03/2019

Company Report

Pages: 5

Viewing the Upcoming Schizophrenia Trials Through the Lens of Literature; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 144

02/27/2019

Company Report

Pages: 6

With Nuplazid Growth Normalizing, We Take a Closer Look at the Schizophrenia Program

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 145

11/07/2018

Company Report

Pages: 6

With a Maturing Catalyst Calendar and Re-Acceleration of Sales, Acadia is Poised to Outperform in 2019, We Believe

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 146

11/01/2018

Daily Note

Pages: 4

Trick or Treat? Stage 1 Results Outweigh Stage 2 Miss, In Our View

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 147

09/21/2018

Daily Note

Pages: 3

Better Safe Than Sorry; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 148

08/09/2018

Company Report

Pages: 5

Revised Guidance Removes Overhang and Creates Attractive Entry; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 149

05/07/2018

Company Report

Pages: 5

Solid Data Package Clears Safety Concerns; Reit Buy and $60PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 150

02/28/2018

Company Report

Pages: 5

Await Pipeline in a Drug Thesis to Unfold; Reit Buy and $60PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 151

11/08/2017

Company Report

Pages: 5

Is Pimavanserin a Pony With Multiple Tricks? Reit Buy with $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 152

10/09/2017

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 153

10/05/2017

Daily Note

Pages: 4

HARMONY Study Initiation: Killing "Multiple" Birds With One Stone? Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 154

08/09/2017

Company Report

Pages: 6

Underlying Marketing Dynamics Give Us Confidence Going Forward; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 155

05/10/2017

Company Report

Pages: 5

Pipeline in a Drug Thesis Should Drive LT Value; Reit Buy and $60 PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 156

03/01/2017

Company Report

Pages: 6

Building a Nuplazid Value Pack: 4Q16 Update

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 157

12/21/2016

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 158

12/21/2016

Daily Note

Pages: 4

ADP Optimism: Pros and Cons

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 10.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 159

12/20/2016

Company Report

Pages: 6

Positive Phase 2 Results in Alzheimer?s Disease Psychosis

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: ACADIA Pharmaceuticals Inc.

Industry: Medical - Biomedical and Genetics

Record: 160

11/08/2016

Company Report

Pages: 6

With Launch on Track, We Applaud Focus on Maximizing Internal Value

Provider: H.C. Wainwright & Co., Inc.

Analyst: FEIN A

Price: 25.00

Research Provided by a Third Party
// eof